DV
Dividend Vision

ESLA — Estrella Immunopharma Inc.

Estrella Immunopharma Inc. (ESLA)

Total return is -92.6% over the past 4.9 years, 179.6 points behind SPY at 87.0%. Its deepest 1-year drawdown was 77.0%.

Estrella Immunopharma is a clinical-stage biopharmaceutical company developing T-cell therapies for blood cancers and solid tumors, with lead candidates EB103 (in Phase I/II trials for diffuse large B-cell lymphoma) and earlier-stage programs targeting additional hematologic malignancies and autoimmune conditions. The company does not currently distribute dividends. Estrella appeals to investors with high risk tolerance who are interested in exposure to early-stage immunotherapy development, as it has not yet commercialized any products.

ESLA key facts

Asset type
Stock
Asset class
Equity
Inception date
09/14/2021
Last close
$0.72
Market cap
$36,148,752
Average volume
9000.0
Beta
0.858
Payout ratio
0.0
Forward P/E
0.0
EPS
$-0.34